Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least 101 rifampicin (RIF) and isoniazid (INH), is a major public health threat that jeopardizes 102 the progress in TB control worldwide [1, 2] . According to an estimation by the World 103
Health Organization (WHO), in 2016 490,000 MDR-TB cases emerged globally, and 104 of these 240,000 died as a result of MDR/RIF-resistant (RR)-TB [1] . Among new and 105 previously treated TB cases, the proportions of MDR/RR-TB cases were 4.1% (95% 106 confidence interval [CI]: 2.8%-5.3%) and 19% (95% CI: 9.8%-27%), respectively [1] . 107
108
China has the third largest number of TB patients worldwide [1] . Despite the steady 109 decline in the overall TB notification rate assigned to the control and CFZ groups, respectively. All recruited patients had a 237 negative test result for the human immunodeficiency virus (HIV). The trial ended on 238 the date of the final follow-up of the patient who was last randomised. During the 239 study period, 39 patients discontinued their treatment (Fig. 1) . The principal reason 240 for discontinued treatment was a failure to follow-up (n=19), followed by treatment 241 modification due to self-reported intolerable adverse events (n=8) and early treatment 242 termination due to serious adverse events (n=8). The demographic and clinical 243 characteristics of the patients were similar in the two study groups. Approximate 95% 244 (132/140) of patients had a previous tuberculosis treatment history, with a medianM A N U S C R I P T
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11 previous treatment duration of 18 months and 24 months for control and CFZ group, 246 respectively. One tenth of patients had comorbidity (Table 1) . 247
248

Treatment efficacy 249
Of the 66 cases analysed for clinical outcome in the CFZ group, 36 patients were 250 cured, and 7 achieved treatment completion who had documented bacteriological 251 conversion through the end of treatment but fewer than three consecutive negative 252 culture, yielding a favourable outcome rate of 65.1%. Out of 23 patients meeting the 253 criteria of adverse outcome, 4 died, 10 defaulted, and 9 failed the treatment in the 254 CFZ group. The proportion of patients with favourable outcomes among those 255 receiving the control regimen was 47.3% (35/74, 26 cured and 9 treatment 256 completion), which was significantly lower than that in the CFZ group (P=0.034, 257 RR=0.661, 95%CI: 0.243-0.949) ( Table 2) . 258
Of the 140 study patients, 101 with culture results were included in Kaplan-Meier 259 analyses. As shown in Fig. 2 , MDR patients in the CFZ group had conversion to 260 culture-negative status sooner than those in the control group by using mycobacterial 261 culture with L-J medium (P=0.031) (Fig. 2) . 262
263
Adverse events 264
A total of 44 adverse events occurred in 44 patients in this study, including 14 in the 265 control group and 30 in the CFZ group. There was a significant difference in the 266 incidence of adverse events between the two groups (P=0.001). Data on the adverse 267 events is detailed in Table 3 . 268 M A N U S C R I P T
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Nine patients (9/44, 20.5%) had serious adverse events, including 3 in the control and 270 6 in the CFZ groups, respectively (Table 3 & Table S4 ). Anti-TB treatment in the 271 control grouped was stopped and not restarted due to a gastrointestinal reaction and an 272 occurrence of anaemia. Also, the adverse effect of the patient suffering 273 gastrointestinal reaction was resolved by stopping treatment, and the initial regimen 274 was reused after one-month of interruption. In the CFZ group, 6 different reactions 275 (two of hepatic damage, two of gastrointestinal reaction, one of renal damage, and 276 one of leukocytopenia) caused serious adverse events; thus, treatments were 277 discontinued and not restarted. The beneficial effect of clofazimine was tempered, as expected, by the high rates of 307 drug-related adverse events. While skin discoloration is the most common adverse 308 event associated with the administration of CFZ [12] , previous studies demonstrated 309 that lowering the dose of clofazimine to 100 mg every other day could help manage 310 the side effects of skin discoloration [12] . However, the effect of decreased exposure 311 to CFZ on clinical outcomes remains unknown. Moreover, hepatic damage (according 312 to our definition) was observed more often patients assigned to the CFZ group 313 compared with patients in the control group, though the difference did not reach 314 statistical significance due to the small sample size. Our findings indicate that routine 315 determination of hepatic enzyme levels should be performed in patients administered 316 the CFZ-containing regimen to avoid the occurrence of severe hepatic injury. 
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